C.R. Bard to shift jobs to NY; AngioDynamics wins CE mark for bypass device;

@FierceMedDev: Veracyte goes public, raises $65M and gains on Day 1. Article | Follow @FierceMedDev

@MarkHFierce: Carlos Slim backs more genomics and Dx work at the Broad Institute, and elsewhere, with a new infusion of $74M. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: ICYMI - Editor's Corner: Nanotech promises new frontier as FDA decides how to regulate. More from FierceDrugDelivery | Follow @MichaelGFierce

> C.R. Bard ($BCR) plans to shift jobs to Queensburg, NY, after two rounds of layoffs last year. Story

> AngioDynamics ($ANGO) gained CE mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for extracorporeal bypass. Item

> SQI Diagnostics will work with Isis Pharmaceuticals ($ISIS) to develop an immunogenicity assay. Item

> Johns Hopkins University spinoff Hemova Medical, developer of a safer vascular access port for kidney dialysis, was among the top winners at this year's MassChallenge awards. Story

> CoActive Medical said it has been awarded a U.S. patent for technology that automatically transmits medical images, voice clips, reports and other patient details over the Internet to authorized users on their computers. Item

Biotech News

@FierceBiotech: Parexel's stock plunges despite spikes in revenue, profit. Report from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @JohnCFierce

@DamianFierce: Do-it-all CRO inVentiv is buying Catalina Health to boost its patient adherence business. News | Follow @DamianFierce

@EmilyMFierce: New survey details impact of federal cuts, sequestration on scientific research. FierceBiotech Research story | Follow @EmilyMFierce

> Roche looks to trump GLP-1 diabetes drugs with a combo approach. More

> Ariad shares plunge again after FDA asks for a halt to Iclusig sales. Story

> Alzheimer's experts team up with Adimab, grab $10M to launch Alector. News

Pharma News

@FiercePharma: Biggest report yesterday: Top 10 Drug Patent Losses of 2014. Feature | Follow @FiercePharma

@CarlyHFierce: CEO Jeremy Levin steps down amid board squabble. Top story yesterday via FiercePharma | Follow @CarlyHFierce

> Who wants to step into Teva's CEO hot seat? Story

> Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates. Article

Pharma Manufacturing News

@EricPFierce: Manufacturing, sanitation issues at Sanofi's Toronto vaccine plant has been a problem for some time now. Story | Follow @EricPFierce

> Foreign cancer-drug dealer gets prison. More

> Space issues lead GSK to close NJ facility, shift production. Report

> DSM opens Australia biologics plant. Story

> India renews duty on Chinese paracetamol. Article

Vaccines News

> Sanofi makes case for Fluzone superior clinical benefit label. News

> GSK, Sanofi join Gates Foundation vaccine R&D initiative. Report

> Vaccines a rare bright spot in Merck's gloomy financials. More

> ACIP recommendation gives Novartis a new growth opportunity. Story

> Dendreon reportedly seeking buyer for struggling business. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.